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Abstract: Enhancer of zeste homolog 2 (EZH2) plays a crucial role in embryonic and 
somatic stem cells for their proliferation and differentiation. However, the roles and 
underlying mechanisms of EZH2 in prostate cancer stem cells (PCSCs) remain unknown. 
This study aimed to investigate the effects of EZH2 on PCSCs. PCSCs were isolated from 
the human prostate cancer cell line LNcap by fluorescence activated cell sorting (FACS). 
EZH2 expression was compared between PCSCs and non-PCSCs. The association between 
EZH2 function and PCSC growth was investigated using siRNA-mediated knock-down of 
EZH2. Cell growth was investigated by MTT, cell cycle and apoptosis of PCSCs were 
explored by flow cytometric analysis. Finally, the upstream pathway miRNA level was 
determined via a luciferase reporter assay, and the downstream pathway cycle regulators 
were examined via reverse transcriptase-polymerase chain reaction. The results showed 
that LNcap cell line comprised a greater proportion of CD44
+/CD133
+ cells by comparison 
to the PC-3 cell line. EZH2 was up-regulated in PCSCs compared with non-PCSCs. 
Silence of EZH2 inhibited cell growth and the cell cycle and promoted the progression of 
apoptosis. Furthermore, EZH2 was a direct target of miR-101 in PCSCs and EZH2’s 
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mRNA levels were inversely correlated with miR-101 expression and cyclin E2   
(a cell-cycle regulator) was suppressed by siEZH2. In conclusion, EZH2 is essential for 
PCSC growth, partly through a negative regulation by miR-101 and positively regulating 
cyclin E2. 
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1. Introduction 
Prostate cancer is one of the most common malignancies in the world. The identification of cells 
that are involved in prostate carcinogenesis has posed a challenge for many decades [1,2]. 
Prostate cancer stem cells (PCSCs) have been identified as a low frequency cell population capable 
of self-renewal and differentiation, which are believed to play an essential role in cancer recurrence 
following therapeutic intervention [3–5]. PCSCs have been isolated from prostate carcinoma and 
prostate cancer cell lines using several methods, including flow cytometry for specific cell surface 
markers, isolation of a side population, and formation of cell spheres [6–9]. Although prostate cancer 
stem cells have been successfully identified, the molecular pathways regulating their generation and 
propagation are poorly understood. 
Enhancer of zeste homolog 2 (EZH2) plays a central role as a catalytic enzyme involved in histone 
methylation [10,11]. Indeed, EZH2 can directly methylate the promoters of transcription factors that 
are essential in sustaining stem cell pluripotency, including Oct-4, Sox-2, and Nanog [12]. Small 
interfering RNA (siRNA) duplexes targeted against EZH2 lead to early embryonic lethality, 
meanwhile EZH2 deficient embryonic stem cell lines cannot be established in vitro [13]. Although 
EZH2 plays a key role during embryogenesis and in a variety of adult stem cells [14–16], little is 
known regarding the influence of EZH2 on prostate cancer stem cells. 
In this study, we investigated the potential involvement of EZH2 in PCSCs. First, we examined the 
expression level of EZH2 in PCSCs as compared to non-PCSCs. Next, we tested the effects of EZH2 
on cell growth, cell cycle and apoptosis by siEZH2. Finally, we explored the mechanisms underlying 
the effect of EZH2 in PCSCs. 
2. Results and Discussion 
2.1. The LNcap Cell Line Contained More CD44
+/CD133
+ Cells 
In order to find a more suitable source of PCSCs, we analyzed the expression of CD44/CD133 in 
PC-3 and LNcap cell lines using FACS. We found that CD44
+/CD133
+ constituted 1.02 ± 0.11% and 
0.32 ± 0.03% of LNcap cells and PC-3 cells, respectively (Figure 1A,B). In all experiments, purity of 
PCSCs (>90%) was confirmed by flow cytometry (Figure 1C).  
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Figure 1. LNcap cell line had more CD44
+/CD133
+ cells. EZH2 is up-regulated in prostate 
cancer stem cells (PCSCs) compared with non-PCSCs. (A) Identification of the percent of 
stem cell like cancer cells in two human prostate cancer cell lines by using flow cytometric 
analysis; (B) Histogram of percent of CD44
+/CD133
+ cells (* p < 0.05) in LNcap and  
PC-3 cell line; (C) In all experiments, purity of PCSCs (>90%) was confirmed by flow 
cytometry. FACS sorted cells were cultured in serum-free medium for 1, 3, 5, 7, 9 days 
respectively, identification of the percent of CD44
+/CD133
+ cells; (D) mRNA expression 
of EZH2 and the putative stem cell markers Oct4, SOX2, Nanog, CXCR4 between PCSCs 
and non-PCSCs; (E) Protein level of of EZH2 and the putative stem cell markers Oct4, 
SOX2, Nanog, CXCR4 between PCSCs and non-PCSCs. 
 
 
2.2. EZH2 Was Up-Regulated in PCSCs Compared with Non-PCSCs 
To confirm expression of previously reported putative stem cell markers in PCSCs, we analyzed 
mRNA and protein levels of Oct4, SOX2, Nanog, CXCR4 between PCSCs and non-PCSCs. Our 
results showed that expression of these stem cell markers were up-regulated in PCSCs compared with 
non-PCSCs. Next, EZH2 expression was measured by qPCR and western blot and results showed 
EZH2 were up-regulated in PCSCs (Figure 1D,E). 
2.3. Silencing of EZH2 Suppressed Proliferation and Inhibits Cell Cycle in PCSCs 
To examine whether EZH2 played a tumor-suppressive function, we investigated the effects of 
EZH2 knockdown on proliferation and cell cycle in PCSCs. Initially, we constructed siEZH2 that can 
readily block the expression of EZH2 in PCSCs (Figure 2A). Subsequently, the MTT assay Int. J. Mol. Sci. 2013, 14  11984 
 
 
demonstrated that siEZH2 reduced cell viability in a time-dependent manner and showed a significant 
difference compared with controls (Figure 2B). PCSCs transfected with siEZH2 showed an increased 
percentage of cells in G1 phase but a decreased percentage of cells in S phase compared with controls 
(Figure 2C–F). Thus, the results revealed that siEZH2 arrested the cell cycle of prostate cancer   
stem cells. 
Figure 2. (A) Protein levels of EZH2 after PCSCs were transfected with siEZH2 and 
negative control; (B) Cell Proliferation ability in PCSCs by MTT assay; (C–E) Silence of 
EZH2 inhibited cell cycle in PCSCs by flow cytometry; (F) Histogram of PCSCs cell cycle 
analysis; (G–I) Silence of EZH2 promoted the progression of apoptosis. Apoptosis was 
analyzed by flow cytometry; (J) Histogram of PCSCs apoptosis. All data are from 3 
separate experiments (* p < 0.05). 
 
 
2.4. Silencing of EZH2 Promoted the Progression of Apoptosis 
To explore the role of EZH2 in regulating cell apoptosis, siEZH2 or a negative control were 
transfected into PCSCs. The transfection of siEZH2 was found to promote the progression of PCSCs 
apoptosis, indicating that EZH2 could inhibit apoptosis of PCSCs (Figure 2G–J). 
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2.5. Cyclin E2 as a Cell-Cycle Regulator Was Suppressed by siEZH2 
The p53 and pRb pathways are involved in the regulation of cell cycle progression and are 
frequently deregulated in cancers. To investigate whether these regulators were involved in the growth 
inhibition by siEZH2, we checked the mRNA levels of 8 regulators by qPCR including cyclin D3 and 
E2, cyclin-dependent kinase 4 and 6 (CDK4, CDK6), c-myc, p14ARF, p21CIP1, and Raf1(Figure 3A). 
And we also examined the following embryonic development regulators: β-catenin, Wnt-1, Wnt-6, 
Wnt-10a and Wnt-10b (Figure 3B). The levels of cyclin E2 decreased after EZH2 knockdown 
compared with its controls.  
Figure 3. (A) RNA levels of 8 cell cycle regulators after PCSCs were transfected with 
siEZH2 and negative control. Cyclin E2 expression decreased significantly after EZH2 
knockdown; (B) RNA levels of several embryonic development regulators after PCSCs 
were transfected with siEZH2 and negative control. 
 
2.6. EZH2 Was a Direct Target of miR-101 in Prostate Cancer Stem Cells 
As previously confirmed, miR-101, miR-124, miR-26a, let-7 can interact with EZH2 in many types 
of cancer, including glioblastoma, prostate, gastric, breast and bladder cancer [17–26].  
Initially, we examined the expression of miR-101, miR-124, miR-26a, let-7 by qPCR between 
PCSCs and non-PCSCs, and found that miR-101 expression was significantly down-regulated in 
PCSCs (Figure 4A).  
To validate whether EZH2 was regulated by miR-101 in PCSCs, we transfected miR-101 mimic 
into PCSCs. As shown, miR101 mimic reduced the EZH2 expression (Figure 4B).  
Next, we transfected miR-101 mimic or the negative control into PCSCs along with the   
psi-CHECK2. By comparison to the negative control, miR-101 mimic significantly suppressed the 
luciferase activity of the reporter plasmid (Figure 4C). These findings indicated that miR-101 bound to 
3ꞌ-UTR of EZH2 and repressed EZH2 expression. 
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Figure 4. EZH2 was a direct target of miR-101 in prostate cancer stem cells. (A) qPCR 
analysis of several reported aberrant miRNA which could interact with EZH2,   
down-regulation of miR-101 was confirmed; (B) miR-101 mimic could significantly 
reduced EZH2 expression compared with controls; (C) Luciferase reporter assays in 
PCSCs: compared with controls, miR-101 mimic group showed a significant difference  
(* p < 0.05). 
  
(A) 
 
(B) 
  
(C) 
2.7. Discussion 
PCSCs have been identified to be a low frequency cell population with a high proliferative   
capacity [6,7]. Although a variety of experimental systems have been previously used to study   
PCSCs [6–8,20,27], the precise mechanisms underlying their generation and propagation had not   
been demonstrated.  
Recent studies have confirmed the important position of EZH2 in maintaining the pluripotency of 
embryonic stem (ES) cells [13]. Following EZH2 knockout, the level of various genes involved in cell 
differentiation and embryonic development (MYT1, CNR1, and WNT1) became down-regulated. 
EZH2 can collaborate with cell growth factors such as OCT-4, SOX-2, and NANOG to maintain stem 
cell pluripotency, thereby promoting the proliferation and suppressing the differentiation of ES   
cells [13,28]. Studies of normal tissue stem cells have demonstrated a unique role for EZH2 in stem Int. J. Mol. Sci. 2013, 14  11987 
 
 
cell activation [14–16]. EZH2 may play a similarly unique role in cancer stem cells or tumor   
initiating cells [29]. 
It’s believed that EZH2 functions mainly through H3K27me3, this kind of methylation leads to 
down-regulation of target genes. However, recent studies indicated that EZH2 could up-regulate target 
genes by H3K36me2 [30]. West et al. revealed breast tumor-initiating cells displayed high expression 
of the pluripotency factor Sox2 [31]. Similar with Sox2, higher expression of Oct4 and Nanog were 
also found in cancer stem cells [32]. Besides, Chang identified increased EZH2 expression in BTICs is 
linked to enhanced BTICs and high grade breast cancer and OCT4 (OCT4
+), the detailed mechanism 
was not illustrated [33]. Recently, Asangani IA discovered that EZH2 could up-regulate target genes 
by H3K36me2 [30], indicating EZH2 could not only repress target genes, but also up-regulate some 
genes in another way. The new function of EZH2 might be able to illustrate why EZH2 and the 
transcription factors including Sox2, OCT4, Nanog are all up-regulated in cancer stem cells. Our study 
revealed that EZH2 mRNA and protein expression was significantly higher in PCSCs than in matched 
non-PCSCs, together with the higher expression of stem cell transcription factors. We speculated that 
EZH2 might up-regulate these factors via H3K36me2 or another similar way. Further study is needed 
in order to elucidate the relationship between EZH2 and these factors in cancer stem cells. 
While investigating the effect of EZH2 on the biological behaviors of PCSCs, we observed that 
siEZH2 inhibited cell growth and G1/S arrest, and induced apoptosis of PCSCs. These data indicated 
that EZH2 was essential for PCSCs growth. However, the mechanisms by which EZH2 influenced cell 
growth were still poorly defined. We checked the expression of important regulators, including p53, 
pRb, and Wnt pathways, and found that knockdown of EZH2 can down-regulate cyclin E2 expression, 
which can then regulate G1/S checkpoint as an oncogene [34,35]. Additionally, we did not observe a 
significant reduction in the expression of any other genes which had shown significant differences 
following EZH2 knockdown. We believe that by down-regulating cyclin E2, siEZH2 can arrest the 
G1/S stage which, in turn, suppressed PCSCs growth. 
Aberrant expressions of miRNAs have been reported in regulation of EZH2. Down-regulation of 
miR-101, miR-124, miR-26a, let-7 have been reported in leading to EZH2 over-expression in   
various kinds of cancer [17–26]. Additionally, these miRNAs have been shown to be implicated in  
cancer-related processes such as cell growth, invasion, and apoptosis [17–26]. We speculate that some 
of these miRNAs may regulate EZH2 expression in PCSCs. We examined the expression of miR-101, 
miR-124, miR-26a, let-7 between PCSCs and non-PCSCs, and found that miR-101 expression was 
inversely correlated with EZH2’s mRNA level. And PCSCs transfected with miR-101 mimic showed a 
dramatic decrease in EZH2 protein level. Furthermore, we found that activity of the luciferase reporter 
with EZH2 3ꞌ-UTR was significantly inhibited in PCSCs transfected with miR-101 mimic compared 
with those transfected with negative and blank controls. These findings provided strong evidence that 
miR-101 can down-regulate EZH2 expression by directly targeting the 3ꞌ-UTR of EZH2 mRNA.  
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3. Experimental Section  
3.1. Cell Culture  
LNCaP and PC-3 human prostate cancer cells were purchased from the American Type Culture 
Collection (ATCC, Manassas, VA, USA). PC-3 and LNcap cell lines were cultured at 37 °C with 5% 
CO2 atmosphere in RPMI-1640, which contained 10% fetal bovine serum (FBS) with 100 IU/mL 
penicillin and 100 µg/mL streptomycin. Prostate cancer stem cells sorted by fluorescence activated cell 
sorting (FACS) were cultured as spheres in a suspension culture system as previously described [36]. 
3.2. Fluorescence Activated Cell Sorting 
To find an efficient method for sorting prostate cancer stem cells from prostate cancer cell lines,  
we measured the expression of the molecular marker CD44
+/CD133
+ using anti-CD44-FITC,   
anti-CD133-phycoerythrin (PE), their corresponding isotype control antibodies (mouse IgG1-FITC and 
IgG1-PE (Miltenyi Biotec Inc, Bergisch Gladbach, Germany)), and a fluorescence activated cell sorter 
(Becton Dickinson, Franklin Lakes, NJ, USA). Cells were harvested, gently disaggregated to a single 
cell suspension, and stained according to the manufacturer’s protocol.  
3.3. RT-PCR Analysis of mRNAs and miRNA Expression 
Total RNA was extracted using the Trizol reagent (Invitrogen, Carlsbad, CA, USA) and reversely 
transcribed using ImProm-II Reverse Transcription System (Promega, Madison, WI, USA) to quantify 
the mRNA levels of Oct4, SOX2, Nanog, CXCR4, EZH2 and cell-cycle regulators, primers were listed 
in the supplement material (See Table S1). RT-PCR was performed using SYBR Green PCR master 
mix (Applied Biosystems, Carlsbad, CA, USA) on an ABI 7500HT system. All RT-PCRs were 
performed in triplicates. 
3.4. Western Blotting 
Cell lysates were separated by 10% SDS-PAGE, and electrophoretically transferred to a 
polyvinylidene difluoride (PVDF) membrane (Millipore Corporation, Billerica, MA, USA). Then the 
membrane was incubated with mouse monoclonal antibody against human EZH2 (Cell Signaling 
Technology, Danvers, MA, USA) followed by horseradish peroxidase (HRP)-labeled goat-antimouse 
IgG (Cell Signaling Technology, Danvers, MA, USA) and detected by chemiluminescence. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a protein loading control. The 
intensity of protein fragments was quantified with the Quantity One software (Bio-Rad Laboratories, 
Hercules, CA, USA). 
3.5. Cell Proliferation Assay 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) substrate (Sigma, St. Louis, 
MO, USA) was used to assay cell proliferation according to the manufacturer’s instructions. Briefly, 
each group of cells was seeded at 1 × 10
3 per well in 96-well plates. Then the MTT reagent (Sigma,  
St. Louis, MO, USA) at a concentration of 5 mg/mL was added to the maintenance cell medium at Int. J. Mol. Sci. 2013, 14  11989 
 
 
different time points (24 h, 48 h, 72 h and 96 h) and incubated at 37 °C for an additional   
4 h. The reaction was terminated with 150 μL dimethylsulfoxide per well. The cells were lysed for  
15 min and the plates were gently shaken for 5 min. Absorbance values were determined using a 
microplate reader (Multiscan MK3, Thermo Fisher Scientific, Waltham, MA, USA) at 490 nm. 
3.6. Cell Cycle Analysis 
Cell cycle analysis was performed to evaluate the impact of EZH2 on PCSCs proliferation. Briefly, 
cells transfected with siEZH2 or controls were washed twice with PBS and fixed overnight with 70% 
ethanol at −20 °C. Cells were washed with PBS and incubated for 30 min at 37 °C in PBS containing 
0.05 mg/mL PI, 1 mmol EDTA, 0.1% Triton x-100, and 1 mg/mL RNase A. Finally, the stained cells 
were analyzed using flow cytometry. 
3.7. Apoptosis Assays 
The Annexin V Apoptosis Detection Kit (BD bioscience, Franklin Lakes, NJ, USA) combined with 
flow cytometry was used to observe the effect of siEZH2 on the induction of apoptosis in PCSCs. 
After incubation with siEZH2, 1 × 10
5 PCSCs were harvested. Next, cells were washed with PBS and 
resuspended in 200 μL of binding buffer. After the addition of 5 μL Annexin V conjugate for 10 min of 
incubation, the samples were resuspended in 200 μL binding buffer and 5 μL propidium iodide (PI). 
Finally, samples were analyzed using the MACS Quant
® analyzer (Miltenyi Biotec Inc, Bergisch 
Gladbach, Germany). Annexin V-positive cells were designated as apoptotic cells. The data were 
analyzed using FlowJo software (Tree Star, Inc, Ashland, OR, USA). 
3.8. Luciferase Reporter Assay 
To examine whether miRNA could directly interact with the 3ꞌ-UTR of EZH2, we created luciferase 
reporter plasmids by cloning 3ꞌ-UTR of EZH2 into a psi-CHECK2. Luciferase reporter was 
constructed by cloning 3ꞌ-untranslated regions (3ꞌ-UTR) of EZH2 mRNA into the XbaI-site of   
psi-CHECK2 (Promega, Madison, WI, USA). PCSCs were transfected with psi-CHECK2 plasmid by 
Lipofectamine 2000 and then cotransfected with miR-101 mimic or a negative control. After 48 h, 
luciferase assays were performed using the Dual-Luciferase assay system (Promega, Madison, WI, 
USA). For each sample, firefly luciferase activity was normalized to renilla luciferase activity. 
3.9. Transient Transfection 
Cells (1 × 10
6) were plated in a low-attachment six-well plate in SFM without antibiotics. The 
EZH2 siRNA, or a negative control oligonucleotide, was transfected into cells with lipofectamine  
2000 (Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s instruction. The concentration 
of EZH2 siRNA was 100 μm. After 6 h of incubation in the CO2 incubator, the medium containing 
siRNA-lipofectamine 2000 complexes was replaced fresh SFM and the cells were cultured for further 
experiments. The specific siRNA sequence was as follows: 5ꞌ-GAAUGGAAACAGCGAAGGA-3ꞌ. A 
non-specific control siRNA was used as a control. The efficiency of RNA interference was monitored 
by fluorescence microscopy and checked by RT-PCR and Western blot analysis. The specific miR-101 Int. J. Mol. Sci. 2013, 14  11990 
 
 
sequence was as follows: UACAGUACUGUGAUAACUGAA. A non-specific control miRNA was 
used as a control. 
3.10. Statistical Analysis 
Statistical analysis was performed using SPSS software 18.0 [37]. Values were presented as   
mean ± standard deviation. Differences were assessed by Student’s T test or analysis of Variance 
(ANOVA). A p value of <0.05 was considered to be statistically significant. 
4. Conclusions  
In summary, EZH2 is essential for PCSCs growth, partly through regulating cyclin E2, and EZH2 
expression is regulated by miR-101. Considering the role of EZH2 in PCSCs and the relationship 
between EZH2 and miR-101, introduction of miR-101 to silence EZH2 could be a potential therapeutic 
strategy for prostate cancer. 
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